## Liang Xu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3688708/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma. Nature Communications, 2022, 13, 1363.	12.8	20
2	MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma. Oncogene, 2021, 40, 1851-1867.	5.9	11
3	PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis. Proceedings of the United States of America, 2021, 118, .	7.1	10
4	Topography of transcriptionally active chromatin in glioblastoma. Science Advances, 2021, 7, .	10.3	19
5	Core transcriptional regulatory circuitries in cancer. Oncogene, 2020, 39, 6633-6646.	5.9	41
6	Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor. PLoS ONE, 2020, 15, e0232068.	2.5	12
7	TP63, SOX2, and KLF5 Establish a Core Regulatory Circuitry That Controls Epigenetic and Transcription Patterns in Esophageal Squamous Cell Carcinoma Cell Lines. Gastroenterology, 2020, 159, 1311-1327.e19.	1.3	92
8	ETV4 is a theranostic target in clear cell renal cell carcinoma that promotes metastasis by activating the pro-metastatic gene FOSL1 in a PI3K-AKT dependent manner. Cancer Letters, 2020, 482, 74-89.	7.2	19
9	SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells. Oncogene, 2019, 38, 6196-6210.	5.9	32
10	<p>Candidate tumor suppressor gene IRF6 is involved in human breast cancer pathogenesis via modulating PI3K-regulatory subunit PIK3R2 expression</p> . Cancer Management and Research, 2019, Volume 11, 5557-5572.	1.9	14
11	LNK suppresses interferon signaling in melanoma. Nature Communications, 2019, 10, 2230.	12.8	21
12	Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma. Nature Communications, 2019, 10, 1353.	12.8	39
13	The Upregulation of Trophinin-Associated Protein (TROAP) Predicts a Poor Prognosis in Hepatocellular Carcinoma. Journal of Cancer, 2019, 10, 957-967.	2.5	31
14	Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations. Haematologica, 2019, 104, 1209-1220.	3.5	30
15	Along with its favorable prognostic role, CLCA2 inhibits growth and metastasis of nasopharyngeal carcinoma cells via inhibition of FAK/ERK signaling. Journal of Experimental and Clinical Cancer Research, 2018, 37, 34.	8.6	33
16	Global expression profiling and pathway analysis of mouse mammary tumor reveals strain and stage specific dysregulated pathways in breast cancer progression. Cell Cycle, 2018, 17, 963-973.	2.6	6
17	dbCoRC: a database of core transcriptional regulatory circuitries modeled by H3K27ac ChIP-seq signals. Nucleic Acids Research, 2018, 46, D71-D77.	14.5	37
18	Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia. Leukemia, 2018, 32, 616-625.	7.2	29

LIANG XU

#	Article	IF	CITATIONS
19	<scp>ROCK</scp> â€dependent phosphorylation of <scp>NUP</scp> 62 regulates p63 nuclear transport and squamous cell carcinoma proliferation. EMBO Reports, 2018, 19, 73-88.	4.5	56
20	The developmental transcription factor IRF6 attenuates ABCG2 gene expression and distinctively reverses stemness phenotype in nasopharyngeal carcinoma. Cancer Letters, 2018, 431, 230-243.	7.2	31
21	Functional Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic Cancer Cells to Dasatinib. Journal of Cancer, 2018, 9, 4762-4773.	2.5	25
22	Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines. BMC Cancer, 2018, 18, 940.	2.6	10
23	Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression. Nature Communications, 2018, 9, 3619.	12.8	179
24	Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5086-E5095.	7.1	87
25	A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study. Journal of Cancer, 2018, 9, 92-99.	2.5	17
26	Mutational profiling of acute lymphoblastic leukemia with testicular relapse. Journal of Hematology and Oncology, 2017, 10, 65.	17.0	16
27	BCL6 promotes glioma and serves as a therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3981-3986.	7.1	58
28	Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma. Gut, 2017, 66, 1358-1368.	12.1	169
29	ZNF750 is a lineage-specific tumour suppressor in squamous cell carcinoma. Oncogene, 2017, 36, 2243-2254.	5.9	90
30	Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia. Cancer Research, 2017, 77, 390-400.	0.9	77
31	Extracellular serglycin upregulates the CD44 receptor in an autocrine manner to maintain self-renewal in nasopharyngeal carcinoma cells by reciprocally activating the MAPK/β-catenin axis. Cell Death and Disease, 2016, 7, e2456-e2456.	6.3	47
32	Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: a meta-analysis. Angiogenesis, 2016, 19, 191-200.	7.2	100
33	CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1–Dependent IGF-1 Signaling. Cancer Research, 2016, 76, 2687-2697.	0.9	29
34	EB-virus latent membrane protein 1 potentiates the stemness of nasopharyngeal carcinoma via preferential activation of PI3K/AKT pathway by a positive feedback loop. Oncogene, 2016, 35, 3419-3431.	5.9	52
35	PDZ binding kinase (PBK) is a theranostic target for nasopharyngeal carcinoma: driving tumor growth via ROS signaling and correlating with patient survival. Oncotarget, 2016, 7, 26604-26616.	1.8	23
36	Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma. Cancer Research, 2015, 75, 1815-1827.	0.9	50

LIANG XU

#	Article	IF	CITATIONS
37	SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway. Journal of Pathology, 2015, 235, 559-570.	4.5	64
38	An emerging role of PARK2 in cancer. Journal of Molecular Medicine, 2014, 92, 31-42.	3.9	88
39	Genomic and molecular characterization of esophageal squamous cell carcinoma. Nature Genetics, 2014, 46, 467-473.	21.4	523
40	The genomic landscape of nasopharyngeal carcinoma. Nature Genetics, 2014, 46, 866-871.	21.4	317
41	Design of hybrid β-hairpin peptides with enhanced cell specificity and potent anti-inflammatory activity. Biomaterials, 2013, 34, 237-250.	11.4	128
42	Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6109-6114.	7.1	59